We hypothesized that IL-6 levels might be associated with the state of anti-tumor immunity related to the treatment effect of eribulin, and so we analyzed the peripheral blood fractions for helper (CD4+) and cytotoxic (CD8+) lymphocytes, Tregs and MDSCs involved in tumor immunity at baseline. This evidence concerns the gene IL6 and neoplasm.